首页> 外国专利> Monoclonal antibody and its Fragments that are directed against cells with INTEGRINS alfavbeta hybridoma Cell Line which producedicho antibodyThe pharmaceutical compositions containing them, a process for their Preparation and the use thereof in tumour processes

Monoclonal antibody and its Fragments that are directed against cells with INTEGRINS alfavbeta hybridoma Cell Line which producedicho antibodyThe pharmaceutical compositions containing them, a process for their Preparation and the use thereof in tumour processes

机译:产生抗体的抗INTEGRINS alfavbeta杂交瘤细胞株的细胞的单克隆抗体及其片段包含它们的药物组合物,其制备方法及其在肿瘤过程中的应用。

摘要

A monoclonal antibody and its fragments have the following characteristics: they react only with the alfav chain of alfaavhuman integrity, and selectively prohibit binding to the cellulose substrate of alfavbeta6 carrier group. The name of hibridoma cell line is 2714d9.f8, which is stored on the access number of DSM acc2331,And it can produce a monoclonal antibody like the top. A pharmaceutical ingredient that includes a monoclonal antibody, such as a description and a vehicle that is superficially acceptable. A procedure for producing monoclonal antibodies, as described above, through mouse immunity with human tumor M21 cell lines. The best way to get cancer treatment by monoclonal antibody is to use a colon cancer cell opulmon,Excluded the location and diagnosis of tumor growth The technical situation describes antibodies against all alfavbeta3 or alfavbeta5 complexes, but does not describe any reagents that selectively inhibit alfavbeta6 series. This is why the present invention provides a monoclonal body, which only reacts with the AV chain of alfav alfav letter of alfav human integrity, selectively blocking the alliance at deintegrina base of alfavbeta 3 and alfavbeta 6 protocells, so-called 14d9.f8.
机译:单克隆抗体及其片段具有以下特征:它们仅与alfaavhuman完整性的alfav链反应,并选择性地禁止与alfavbeta6载体基团的纤维素底物结合。纤毛瘤细胞系的名称为2714d9.f8,该名称存储在DSM acc2331的访问号上,它可以像顶部一样产生单克隆抗体。包含单克隆抗体(例如说明书)和表面可接受的媒介物的药物成分。如上所述,通过小鼠对人肿瘤M21细胞系的免疫来产生单克隆抗体的方法。通过单克隆抗体获得癌症治疗的最佳方法是使用结肠癌细胞,排除肿瘤生长的位置和诊断技术状况描述了针对所有alfavbeta3或alfavbeta5复合物的抗体,但未描述任何选择性抑制alfavbeta6系列的试剂。这就是为什么本发明提供仅与阿尔法夫人类完整性的阿尔法夫阿尔法夫的AV链反应,选择性地阻断在阿尔法贝塔3和阿尔法贝塔6原型细胞的integrina的碱基的联盟的单克隆体的原因,所谓的14d9.f8。

著录项

  • 公开/公告号AR014464A1

    专利类型

  • 公开/公告日2001-02-28

    原文格式PDF

  • 申请/专利号AR1999P100258

  • 发明设计人

    申请日1999-01-22

  • 分类号C07K16/28;A61K39/395;C12N5/20;C12P21/08;

  • 国家 AR

  • 入库时间 2022-08-22 01:26:21

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号